Positive Outcomes of Denosumab Treatment in 2 Patients With Cherubism.
J Oral Maxillofac Surg
; 78(12): 2226-2234, 2020 12.
Article
em En
| MEDLINE
| ID: mdl-32649899
ABSTRACT
Cherubism is a rare autosomal dominant disease whose severity ranges widely, from asymptomatic to life-threatening. Bilateral symmetrical painless expansion of the mandible and maxilla resulting in a typical appearance of the face resembling a cherub, are the highlighted features of the condition. In most cases, cherubism-induced lesions in the jaws appear around the age of 3 years and tend to expand and increase in numbers until puberty. Treatment options for cherubism range from observation to surgical correction and various pharmacologic therapies. Given the excess sensitivity of cherubism osteoclasts to RANKL (receptor activator of nuclear factor κB ligand) and the positive effects of denosumab (XGEVA; Amgen, Thousand Oaks, CA) treatment in patients with giant cell granuloma, we have designed a treatment based on denosumab for 2 cherubism patients that achieves what we consider promising results.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Querubismo
/
Denosumab
Limite:
Humans
Idioma:
En
Revista:
J Oral Maxillofac Surg
Ano de publicação:
2020
Tipo de documento:
Article